Continue to Site

Drug Discovery and Development

AbbVie and Gedeon Richter unveil neuropsychiatric alliance

By |

AbbVie/Gedeon RichterAbbVie (NYSE:ABBV) and Gedeon Richter have formed a co-development and license agreement focused on novel dopamine receptor modulators with the potential to treat neuropsychiatric diseases.

Lake Bluff, Illinois-headquartered AbbVie and Budapest, Hungary-based Gedeon Richter have already collaborated for 15 years in central nervous system projects, including the development of cariprazine (Vraylar/Reagila), which is now authorized to treat conditions such as schizophrenia and bipolar disorder.

Richter has identified several new chemical entities to pursue with Gedeon Richter and has already performed preclinical research on them.

“In collaboration with Richter, we will continue to build on our research that seeks to provide additional insights into our understanding of cariprazine’s clinical pharmacology and explore novel chemistry to identify new dopamine receptor modulators,” said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie, in a statement.

Under terms of the agreement, Richter will get an upfront payment with more cash continent on meeting development, regulatory and commercialization milestones. In addition, Gedeon Richter may also be eligible for sales-based royalties.

Filed Under: Drug Discovery and Development, Neurological Disease
Tagged With: , , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development